期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 15, 期 5, 页码 292-309出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2018.30
关键词
-
类别
资金
- European Union's Horizon Programme [634570]
- European Research Council (ERC Advanced Grant ERC-BRCA)
- Eve Appeal
- National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre
- National Institute for Health Research [ACF-2016-18-013, NIHR-INF-0405] Funding Source: researchfish
- Gynaecology Research Fund (The Eve Appeal) [537839, 537284, 527844] Funding Source: researchfish
The incidence of cancer is continuing to rise and risk-tailored early diagnostic and/or primary prevention strategies are urgently required. The ideal risk-predictive test should: integrate the effects of both genetic and nongenetic factors and aim to capture these effects using an approach that is both biologically stable and technically reproducible; derive a score from easily accessible biological samples that acts as a surrogate for the organ in question; and enable the effectiveness of risk-reducing measures to be monitored. Substantial evidence has accumulated suggesting that the epigenome and, in particular, DNA methylation-based tests meet all of these requirements. However, the development and implementation of DNA methylation-based risk-prediction tests poses considerable challenges. In particular, the cell type specificity of DNA methylation and the extensive cellular heterogeneity of the easily accessible surrogate cells that might contain information relevant to less accessible tissues necessitates the use of novel methods in order to account for these confounding issues. Furthermore, the engagement of the scientific community with health-care professionals, policymakers and the public is required in order to identify and address the organizational, ethical, legal, social and economic challenges associated with the routine use of epigenetic testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据